AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05979207 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMV367
Description: Single dose
Study NCT05979207 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: P. falciparum IBSM infection
Description: Induced Blood Stage Malaria
Study NCT05129332 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Vaginal Moisturizer
Description: Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
Study NCT05622643 — intervention group
Intervention type: OTHER
Intervention: MRI
Description: Comparison between groups
Study NCT04897035 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dayspring Active Wearable Compression System
Description: Dayspring Active Wearable Compression System
Study NCT05129332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vaginal Moisturizer
Description: Natural oil-based vaginal moisturizers, like Vitamin E Oil or Coconut Oil, will be applied topically (dime-size amount) on the labia externally and vagina internally nightly, but at least 3 times per week.
Study NCT05129332 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vaginal Dilator
Description: Vaginal dilator will be inserted vaginally and used daily, but at least 3 times per week.
Study NCT05729308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal epidural block
Description: The patient will be positioned in prone position, sterilized from the iliac crest margin to the lower buttock. Sacral horns will be palpated and sacral hiatus and epidural area will be determined at S4-S5 level through the ultrasound guidance using SonoSite M Turbo(USA).The scanning probe is the linear multi-frequency 6-13 MHz transducer (L25 x 6-13 megahertz linear array)that is covered in sterile plastic bag.Short axis (transverse view) is used first to identify the two sacral cornua as two hyperechoic reverse U-shaped structure Frog sign and the sacrococcygeal ligament in between and epidural space beneath. An 18-gauge epidural needle (length 90 mm) is used for direct puncture of sacrococcygeal membrane out of plane then the probe is rotated to long axis (longitudinal view) and the needle is seen in plane in the epidural space. Injection of 30 ml 0.25% bupivacaine will expand the epidural space
Study NCT05729308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bilateral erector spinae plane block
Description: The patient will be in the prone position, after skin sterilization, ESP block will be performed at the level of T12. A curvilinear high-frequency ultrasound transducer will be placed sagittal 3 cm lateral to T12 spinous process where a hyperechoic shadow of the transverse process (TP) and erector spinae will be defined. A 22-gauge spinal needle will be inserted in cranial to caudal direction toward TP in plane to the ultrasound transducer until the needle touches the TP crossing the whole muscles. The location of the needle tip will be confirmed by visible normal saline solution separating erector spinae muscle off the bony shadow of the TP on ultrasound imaging. After confirming the needle site, 15 mL of 0.25% bupivacaine will be injected. The procedure will be repeated following the same steps on the other side
Study NCT05729308 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia with intravenous analgesia.
Description: * Multimodal therapy with acetaminophen, and nonsteroidal anti-inflammatory drugs (NSAIDs) will be used.~* Vital data will be monitored as mentioned Intraoperatively, if the pulse rate and/or mean blood pressure increased above 20% of the baseline, IV fentanyl will be administered as an incremental dose of 50 µg.~* The patients will be monitored for heart rate and blood pressure at regular 10-minute intervals. If blood pressure decreased more than 20% from baseline, then the patient will receive 500 mL saline infusion; if no response is seen, then 5 mg ephedrine will be administered. If heart rate decreased to 45 beats per minute, an IV injection of 0.1 mg /kg atropine will be administered.
Study NCT06514976 — intervention group
Intervention type: DRUG
Intervention: Cytoflavin
Description: Cytoflavin solution for infusions. 20-40 ml/day (10 ml with the interval of 8-12 hours for 10 days; the single dose is increased up to 20 ml in case of the severe form of the disease) by intravenous drop infusion in dilution per 100-200 ml of 0.9% sodium chloride solution for 10 days; rate of administration: 3-4 ml/min
Study NCT06003205 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Wearable bioimpedance sensor
Description: The investigational device is an electronic bioimpedance-based, body-worn, battery-powered sensor intended to monitor changes in fluid volume. It is designed as an adhesive patch with four integrated electrodes.
Study NCT05253768 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplant (FMT)
Description: Patients will randomized to a fecal microbiota transplantation by using a nasointestinal tube for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of FMT is 200ml at one time. Patients are given the same lifestyle guidance and nutritional advice.
Study NCT05253768 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline and glycerin/food coloring
Description: Patients will receive an equivalent volume of normal saline and glycerin/food coloring via a nasointestinal tube (sham transplantation) for 3 times in 4 weeks(0,2,4) without undergoing an enema before the treatment.~The amount of placebo FMT is 200ml at one time. Patients are given the same lifestyle guidance and nutritional advice.
Study NCT04969705 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: 60 Patients will be randomly divided into three equal groups:~Group A (n=20) : spinal anesthesia with Dexmedetomidine (5µg ) added to local anesthetic (bupivacaine Hcl ) (10 mg) given intrathecally .~Group B (n=20) : spinal anesthesia using local anesthetic( bupivacaine Hcl) (20 mg) combined with TAP block using Dexmedetomidine (20µg ) after the cesarean section~Group C (n=20) (controlled group ) : Spinal anesthesia using only local anesthetic (bupivacaine Hcl ) (10 mg) .
Study NCT05614310 — intervention group
Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Participants will be asked to lie in the MRI scanner while we collect 3D T1- and T2-weighted images and a 3D FLAIR image to exclude pathology (e.g. stroke). Participants will ingest a glucose solution (75 g Dextrose) so dynamic glucoCEST images can be acquired to measure glucose uptake and clearance.
Study NCT05614310 — intervention group
Intervention type: OTHER
Intervention: Blood Glucose Assessment
Description: A blood testing meter will be used to measure the blood sugar levels before and after the scans. Normal reading for a nondiabetic person after fasting is 70-99 mg/dl (3.9-6 mmol/L). If abnormal blood sugar levels are detected (sugar levels outside the above normal range), the participant will no longer be eligible for the study and they will be withdrawn.
Study NCT05614310 — intervention group
Intervention type: OTHER
Intervention: Positron Emission Tomography (PET)
Description: Participants will be administered a radioactive glucose analogue, 2-deoxy-2-(18F) fluoro-D-glucose (18FDG) through a canula inserted into a vein in the arm or hand and asked to sit quietly for 1 h. After 1 h they will be asked to lie quietly and without talking in the PET scanner and a PET brain scan will be performed.
Study NCT05614310 — intervention group
Intervention type: OTHER
Intervention: Cognitive Assessment
Description: Participants will be asked to undertake two cognitive tests (the Alzheimer's Disease Assessment Scale ADAS-cog test and the Mini Mental State Examination test - MMSE). These are standard clinical tests used to determine cognitive dysfunction in Alzheimer's disease.
Study NCT05689567 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEFOG glasses(peripheral focus-out glasses)
Description: Subjects in the intervention group will wear peripheral focus-out glasses ≧8 hours a day and ≧5 days a week.
Study NCT06097871 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Skin Nutraceutical Supplement
Description: The Skin Nutraceutical Supplement is made with Nutrafol's patented Synergen Skin Complex®, which is a blend of proprietary formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties combined to synergistically combat the multiple underlying factors that compromise skin health. These ingredients include Holy Basil, Maca, Curcumin, and Berberine in combination with other nutrients used to support skin health such as olive extract (20% hydroxytyrosol), konjac root (3% ceramides), vitamin A, B vitamins, and vitamin C.
Study NCT06097871 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill
Description: A placebo pill containing non-active ingredients
Study NCT05680142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: superficial cervical plexus block
Description: The superficial cervical plexus block is applied as part of our routine protocol for postoperative pain control. Group sCPB will be administered from the C4 level by entering the posterior border of the sternocleidomastoid muscle from the right side of the neck.
Study NCT05680142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cervical erector spinae plane block
Description: The cervical erector spinae plane block is applied as part of our routine protocol for postoperative pain control. Group cESP is applied to the fascia between the semispinalis capitis muscle and the posterior scalene muscle of the C6 or C7 transverse process.
Study NCT05464082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Precision Oncology
Description: Patient derived models (PDMs), comprising patient derived xenografts (PDXs) and organoids (PDO and PDxO),
Study NCT05471336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Enteral Feeding
Description: Feeds of expressed breast milk or donor breast milk will be given. Formula feeds will not be permitted. If the parents do not wish to provide donor milk, whatever volume of expressed mother's milk is available will be given up until the required volume. Feeds will be administered via orogastric or nasogastric tube and administered over 30 minutes.
Study NCT04677387 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nalox-comm Training Module
Description: The online communication module will be 30-60 minutes. Content will include: 1) using non-judgmental language, 2) how to raise the topic of overdose (OD) and naloxone with patients in a non-threatening manner; 3) videos modeling how to initiate the conversation with patients and caregivers; 4) considerations in how to communicate differently with patients versus caregivers; and 5) addressing pharmacists' perceived barriers to naloxone counseling. Pharmacists can receive continuing education credit (0.1 CEU) for completing the course.
Study NCT04677387 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Prescribe to Prevent: Overdose Prevention and Naloxone Rescue Kits for Prescribers and Pharmacists
Description: A 55 minute long online module with videos, didactic content, and quizzes that covers the following topics: risk factors for overdose (OD), how to respond to OD, how naloxone works, types of naloxone, how to administer naloxone, medico-legal issues, how to bill for naloxone, and strategies to address overdose. Pharmacists can receive continuing education credit (0.125 CEUs) for completing the course.
Study NCT04819750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MusicCare® device
Description: The device is a touch tablet with a headset that allows noise reduction. The patient can choose the music they prefer. The selected U-shaped sequence uses the principles of hypnoanalgesia to accompany the patient into a state of deep relaxation.
Study NCT04819750 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Headphones with noise reduction
Description: Headphones with noise reduction without music
Study NCT04685356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IBAIP : Infant Behaviour Assessment and Intervention Program
Description: The IBAIP intervention program consists of providing an intervention with the child and their family, at home, upon discharge from hospital and up to a corrected age of 6 months. Interventions therefore take place at the early stage of the child's brain development. The intervention is performed by a IBAIP-trained and certified physiotherapist or psychomotor therapist trained , at the rate of one session per month over a period of approximately 6 to 8 months (6 months of corrected age). The session takes place in the child's usual living environment, at home, in the presence of at least one of the parents. It focuses on the child's behaviors and consists of assisting the family in its interactions with the child so that these are adapted and responsive to the child's development needs over time through repeated interventions.
Study NCT04685356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Support
Description: One medical consultation per month and, if indicated by the physician providing follow-up, medical specialist and / or paramedical (physiotherapy, speech therapy, psychomotricity, etc.) consultations including interventions in the case of developmental delays
Study NCT04685356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ages and Stages Questionnaire (ASQ)
Description: Global development screening tool
Study NCT04685356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ages and Stages Questionnaire (ASQ)
Description: Global development screening tool
Study NCT04685356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Stress Index (PSI)
Description: Index used to detect difficulties sufficiently significant that they might require psychosocial intervention
Study NCT04685356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Parenting Stress Index (PSI)
Description: Index used to detect difficulties sufficiently significant that they might require psychosocial intervention
Study NCT04685356 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bayley Scales of Infant and Toddler Development (BSID-III)
Description: This test was designed to measure the development of infants / young children. This assessment examines all spheres of child development, identifies children with developmental delay and assesses children's developmental performance compared to their peers.
Study NCT04685356 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bayley Scales of Infant and Toddler Development (BSID-III)
Description: This test was designed to measure the development of infants / young children. This assessment examines all spheres of child development, identifies children with developmental delay and assesses children's developmental performance compared to their peers.
Study NCT06277713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standing interruptions
Description: A mobile sit-to-stand desk will be installed at the workplace and participants are instructed to alternate their working position every 30 minutes during two working days (8h).
Study NCT06277713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise bout
Description: Participants will perform a continuous aerobic exercise bout for a duration of 60 minutes at a moderate intensity, which is defined as 60% of their maximal oxygen uptake (VO2max).
Study NCT06277713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise bout
Description: Participants will perform a continuous aerobic exercise bout for a duration of 60 minutes at a moderate intensity, which is defined as 60% of their maximal oxygen uptake (VO2max).
Study NCT06277713 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sedentary
Description: Participants are instructed to minimise any behaviour that is not sedentary during two working days (8h).
Study NCT06277713 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Sedentary
Description: Participants are instructed to minimise any behaviour that is not sedentary during two working days (8h).
Study NCT05042986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: .[14C]-SKI-O-703
Description: Single oral dose of 200 mg (100 μCi in 200 mg salt \[0.5 μCi/mg as salt\], equivalent to 100 μCi in 142 mg active \[0.7 μCi/mg as active\]) of \[14C\]-SKI-O-703 containing approximately 100 μCi of \[14C\]-SKI-O-703 per capsule after an overnight fast.
Study NCT05497817 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Algorithm
Description: Current and/or former Care Partners of persons with dementia will be matched using an algorithm to other Care Partners who might provide emotional support.
Study NCT05497817 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Random Match
Description: Current and/or former Care Partners of persons with dementia will be randomly matched to other Care Partners who might provide emotional support.
Study NCT05910970 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adjuvant tislelizumab plus lenvatinib
Description: Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab plus lenvatinib treatment for six months, HCC recurrence, or unacceptable adverse events.
Study NCT05910970 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adjuvant tislelizumab
Description: Patients at high-risk of hepatocellular carcinoma recurrence after curative resection or ablation will receive adjuvant tislelizumab treatment for six months, HCC recurrence, or unacceptable adverse events.
Study NCT05057338 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CoreDISTparticipation
Description: CoreDISTparticipation is a thorough intervention that contains coordination of services (physiotherapy, MS-nursing and work adaptations) between the MS-OP clinic and the municipality aiming to improve function, physical activity and employment in individuals with MS.
Study NCT05057338 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: The standard care group will follow regular consultations at the MS-outpatient clinic including a session with the physiotherapist. Furthermore, this group will follow usual care in the municipality which might include other forms of physiotherapy or physical activity. These will be registered.
Study NCT05269862 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature
Description: Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted in-clinic (not using the Virtual Clinic feature).
Study NCT05269862 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Abbott Infinity DBS systems with the NeuroSphere Virtual Clinic feature (virtual clinic and in-clinic sessions)
Description: Implant and initial programming of the Infinity DBS system for this cohort are conducted according to the sites standard of care. After initial programming, all follow-up programming for the first 3 months is conducted using Virtual Clinic or in-clinic as appropriate.
Study NCT05588583 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mepilex Up
Description: Mepilex Up is a highly conformable dressing that absorbs both low and high viscous exudates, maintains a moist wound environment and minimises the risk of maceration. The dressing has a Safetac® wound contact layer that is a unique adhesive technology. It minimises pain to patients and trauma to wounds and the surrounding skin at dressing removal.~Mepilex Up consists of:~* a soft silicone wound contact layer (Safetac)~* a flexible absorbent pad of compressed polyurethane foam~* an outer polyurethane film which is breathable but waterproof~Dressing material content:~Silicone, polyurethane
Study NCT06202768 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data collection : age, gestational age, BMI, history of vaginal delivery after cesarean section, indication for cesarean section, preeclampsia for this pregnancy, the cervix dilatation, position in the pelvis, cervix consistency
Study NCT06445088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: VCA-IgA, EBNA1-IgA, and EBV-DNA
Description: Detect VCA-IgA, EBNA1-IgA, and EBV-DNA for all participants.
Study NCT06445088 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: EBV C Promoter Methylation Detection in nasopharyngeal swab samples
Description: Detection of methylation status of Epstein-Barr virus C promoter in human nasopharyngeal swab samples
Study NCT05226676 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive and painless brain stimulation technique that allows the brain excitability to change based on Faraday's Law of Electromagnetic induction . Since the presentation of the CNP is usually bilateral, the coil will be targeting the dominant hand abductor pollicis brevis (APB) muscle. If the pain is more intense in one of the arms, that arm will be targeted. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
Study NCT05226676 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial Magnetic Stimulation
Description: Transcranial magnetic stimulation (TMS) is a non-invasive and painless brain stimulation technique that allows the brain excitability to change based on Faraday's Law of Electromagnetic induction . Since the presentation of the CNP is usually bilateral, the coil will be targeting the dominant hand abductor pollicis brevis (APB) muscle. If the pain is more intense in one of the arms, that arm will be targeted. This protocol was developed in accordance with the guidelines for the safe use of rTMS.
Study NCT05790070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Betaine
Description: 3g/ twice daily (separated by \~12 hours) betaine anhydrous